SMAD4 and cervical carcinoma: An analysis of 178 cervical carcinomas by The Cancer Genome Atlas (TCGA) network found recurrent deletions of TGF-beta receptor 2 (TGFBR2, 3p24.1) and SMAD4 (18q21.2) in 36% and 28% of analyzed samples, respectively [30].